Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapamycin in lung transplantation.

R Laporta Hernández1, P Ussetti Gil, C García Gallo

  • 1Lung Transplant Unit, Clínica Puerta de Hierro, Madrid, Spain. roslaporta@arsytel.com

Transplantation Proceedings
|January 3, 2006
PubMed
Summary

Rapamycin (RAPA) can stabilize or improve lung function in lung transplant recipients with bronchiolitis obliterans (BOS). Close monitoring for adverse effects, particularly infections, is crucial during RAPA treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current Situation and Prognostic Evolution of Combined Heart-lung Transplantation in a European Union Country.

International journal of organ transplantation medicine·2023
Same author

Follow-up with Telemedicine in Early Discharge for COPD Exacerbations: Randomized Clinical Trial (TELEMEDCOPD-Trial).

COPD·2020
Same author

Lung Transplantation in Pulmonary Hypertension: A Multidisciplinary Unit's Management Experience.

Transplantation proceedings·2018
Same author

Multidetector computed tomography shows reverse cardiac remodeling after double lung transplantation for pulmonary hypertension.

Radiologia·2016
Same author

Is gammaglobulin anti-CMV warranted in lung transplantation?

Transplantation proceedings·2006
Same author

[Management of diabetes in hospitalized patients].

Anales de medicina interna (Madrid, Spain : 1984)·2005

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Bronchiolitis obliterans (BOS) is a significant complication in lung transplant recipients.
  • Rapamycin (RAPA) possesses immunosuppressive and antiproliferative properties, suggesting potential therapeutic value in BOS.
  • This study investigates RAPA's efficacy in patients with refractory BOS.

Purpose of the Study:

  • To evaluate the effectiveness of Rapamycin (RAPA) in lung transplant recipients with bronchiolitis obliterans (BOS).
  • To assess changes in pulmonary function and identify adverse events associated with RAPA treatment in BOS patients.

Main Methods:

  • Retrospective analysis of 11 lung transplant recipients with BOS treated with RAPA.
  • Evaluation of clinical characteristics, pulmonary function (FEV1), and complications.

Related Experiment Videos

  • RAPA was administered in conjunction with calcineurin inhibitors and steroids.

    • Main Results:

    • 72% of patients (8/11) demonstrated improved or stabilized FEV1 after RAPA initiation.
    • Common adverse effects included infections (6/12) and myelosuppression (3/11).
    • Treatment withdrawal due to adverse effects occurred in 2 patients.

    Conclusions:

    • Rapamycin (RAPA) may stabilize or improve pulmonary function in lung transplant recipients with BOS.
    • Close patient monitoring is essential to detect and manage potential adverse effects, especially infections.